Compare ADT Inc (ADT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADT Inc vs State Street SPDR S&P Biotech ETF — how do they compare? ADT Inc trades at $7.33 (market cap $5.44B), while State Street SPDR S&P Biotech ETF trades at $159.46. The key difference: ADT Inc pays a 2.95% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, ADT Inc nearer its low. Which is the better fit depends on your goals.
| ADT | XBI | |
|---|---|---|
Market Cap | $5.44B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $8.85 | $164.28 |
52-Week Low | $6.30 | $86.92 |
Enterprise Value | $13.13B | — |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADT trades at $7.31, down 2.66% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company shows solid fundamentals with a P/E of 10.35, net income margin of 11.86%, and consistent revenue growth, supported by positive analyst sentiment and institutional buying.
Outlook remains positive due to strong cash flow, dividend payments, and AI integration, but risks include high debt levels and competitive pressures. Wall Street consensus leans bullish with 47% buy ratings, suggesting potential upside if execution continues.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADT Inc
ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.
Read more on ADT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
